KEYTRUDA (Pembrolizumab)-100mg

KEYTRUDA (Pembrolizumab) is an immunotherapy that works by blocking the PD-1, a protein that prevents T cells from recognizing and attacking inflamed tissues and cancer cells. By blocking PD-1, pembrolizumab increases your immune system’s ability to attack melanoma cells and tumors. The drug works to unleash T cells so that they can invade melanoma anywhere in your body.

Pembrolizumab is a monoclonal antibody, an anti-PD-1 (checkpoint) inhibitor that promotes the tumor-killing effects of T cells (white blood cells that help your body fight disease) and is indicated for:

• Treatment of recurrent or metastatic cervical cancer
• Treatment of recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
• As an adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection (melanoma skin cancer)
• Treatment of patients with metastatic non-small cell lung cancer (NSCLC)
• Bladder cancer
• Hodgkin lymphoma